This clinical trial is focused on studying a condition known as sepsis-induced hypotension, which occurs when a severe infection leads to dangerously low blood pressure. The study will evaluate a treatment using a medication called REGN7544, which is a type of protein designed to help manage this condition. REGN7544 is administered as a solution for injection through an intravenous infusion, meaning it is delivered directly into the bloodstream.

The purpose of the study is to assess how well REGN7544 can reduce the need for medications called vasopressors, which are used to raise blood pressure in patients with sepsis-induced hypotension. Participants in the study will receive either REGN7544 or a placebo, and the effects on their blood pressure and overall health will be monitored. The study will also look at the safety of REGN7544 and how the body processes the medication.

Throughout the study, researchers will collect information on various health indicators, such as blood pressure levels and the amount of vasopressors needed. They will also monitor for any side effects and measure the levels of REGN7544 in the blood. The study aims to provide valuable insights into the potential benefits of REGN7544 for patients with sepsis-induced hypotension.